Foundayo Alternatives & Comparison

The strongest injectable against the first non-peptide pill. SURMOUNT-1 reported −20.9% at 72 weeks for Zepbound; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo — different trials, but both at 72 weeks in obesity, which makes the comparison unusually readable for a cross-trial one. Neither has published cardiovascular outcomes. Zepbound is $349–$499 through LillyDirect; Foundayo's direct-pay tier is still rolling out. Roughly: more weight loss, or no needle and no cold chain.

STEP-1 reported −14.9% at 68 weeks for Wegovy; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo. Close enough that delivery and cost may decide it — but Wegovy carries the completed cardiovascular outcome, MACE −20% in SELECT, and Foundayo has no MACE data yet. That is a real asymmetry rather than a footnote: one has been shown to prevent events, the other has been shown to reduce weight. Wegovy runs $349–$499 through NovoCare; Foundayo's pricing is still landing.

Both are taken every day; only one requires an injection. SCALE Obesity reported about −8.0% at 56 weeks for Saxenda, ATTAIN-1 −11.1% at 72 weeks for Foundayo. The commercial picture is one-sided: Saxenda lists near $1,400 with no manufacturer cash-pay program, and Foundayo arrives with LillyDirect pricing pending. For a daily-dosing patient with no strong reason to inject, the pill is the more obvious starting conversation.